TCRT (Alaunos Therapeutics) Float Percentage Of Total Shares Outstanding: 91.89% (As of Jul. 06, 2026)


TCRT Alaunos Therapeutics Inc TCRT
28 GF Score
Price $2.08
GF Value $0.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alaunos Therapeutics Float Percentage Of Total Shares Outstanding?

Alaunos Therapeutics TCRT -4.37% 28 Float Percentage Of Total Shares Outstanding is 91.89% as of Jul. 06, 2026. GuruFocus rates TCRT with a GF Score™ of 28/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alaunos Therapeutics's float shares is 2.24 Mil. Alaunos Therapeutics's total shares outstanding is 2.44 Mil. Alaunos Therapeutics's float percentage of total shares outstanding is 91.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alaunos Therapeutics's Insider Ownership is 63.06%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alaunos Therapeutics's Institutional Ownership is 6.40%.

TCRT
28GF Score
Alaunos Therapeutics Inc TCRT
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alaunos Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Alaunos Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=2.24/2.44
=91.89%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 91.89% mean?
Alaunos Therapeutics (TCRT) has a Float Percentage Of Total Shares Outstanding of 91.89% as of Jul. 06, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Alaunos Therapeutics and its competitors.
Is Alaunos Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Alaunos Therapeutics' current Float Percentage Of Total Shares Outstanding is 91.89%. Overall, Alaunos Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alaunos Therapeutics' Float Percentage Of Total Shares Outstanding compare to DRMA and MBIO?
Alaunos Therapeutics' Float Percentage Of Total Shares Outstanding of 91.89% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Alaunos Therapeutics and its competitors. Alaunos Therapeutics's current Float Percentage Of Total Shares Outstanding is 91.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alaunos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.08 — trading 205.9% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 91.89%. Alaunos Therapeutics' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current Float Percentage Of Total Shares Outstanding is 91.89% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alaunos Therapeutics (TCRT) Overvalued in 2026?

Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued. The current stock price of $2.08 is trading 205.9% above its estimated GF Value™ of $0.68. GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.

Key valuation signals for TCRT:

  • Float Percentage Of Total Shares Outstanding: 91.89%
  • GF Value™: $0.68 vs. price of $2.08 (205.9% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alaunos Therapeutics Business Description

Address 501 East Las Olas Boulevard, Suite 300, Fort Lauderdale, FL, USA, 33301
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
28GF Score

Get the complete analysis for TCRT

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price
$0.68
GF Value